Bringing medical inn vation to life Orchestra BioMed Corporate Presentation July 2022 Important Notice and Disclaimer This investor presentation (this "Presentation") is for informational purposes only to assist interest

Bringing medical inn vation to life Orchestra BioMed Corporate Presentation July 2022

Important Notice and Disclaimer This investor presentation (this "Presentation") is for informational purposes only to assist

interested parties in making their own evaluation with respect to the proposed business combination (the "Business Combination") between Health Sciences Acquisitions Corporation 2 ("HSAC2") and Orchestra BioMed, Inc. ("OBIO," "Orchestra," or the

"Company") and for no other purpose. The information contained herein does not purport to be all-inclusive and none of HSAC2, the Company or their respective affiliates makes any representation or warranty, express or implied, as to the accuracy,

completeness or reliability of the information contained in this Presentation. Neither the Company nor HSAC2 has verified, or will verify, any part of this Presentation. The recipient should make its own independent investigations and analyses of

the Company and its own assessment of all information and material provided, or made available, by the Company, HSAC2 or any of their respective directors, officers, employees, affiliates, agents, advisors or representatives. This Presentation

does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to

purchase any security of HSAC2, the Company, or any of their respective affiliates, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification

under the securities laws of any such jurisdiction. No offering of securities shall be made expect by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended (the "Securities Act"). You should not construe

the contents of this Presentation as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and,

by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision. The distribution of this Presentation may also be restricted by law and persons into whose possession this

Presentation comes should inform themselves about and observe any such restrictions. The recipient acknowledges that it is (a) aware that the U.S securities laws prohibit any person who has material, non-public information concerning a company

from purchasing or selling securities of such company or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities, and (b)

familiar with the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the "Exchange Act"), and that the recipient will neither use, nor cause any third party to use, this Presentation

or any information contained herein in contravention of the Exchange Act, including, without limitation, Rule 10b-5 thereunder. This Presentation and information contained herein constitutes confidential information and is provided to you on the

condition that you agree that you will hold it in strict confidence and not reproduce, disclose, forward or distribute it in whole or in part without the prior written consent of HSAC2 and the Company and is intended for the recipient hereof

only. Forward-Looking Statements This Presentation may contain forward-looking statements. Forward-looking statements include, without limitation, statements regarding the estimated future financial performance and financial position of the

Company. Future results are not possible to predict. Opinions and estimates offered in this Presentation constitute the Company's judgment and are subject to change without notice, as are statements about market trends, which are based on

current market conditions. This Presentation contains forward-looking statements, including without limitation, forward-looking statements that represent opinions, expectations, beliefs, intentions, estimates or strategies regarding the future of

the Company and its affiliates, which may not be realized. Forward-looking statements can be identified by the words, including, without limitation, "believe," "anticipate," "continue," "estimate," "may," "project," "expect," "plan," "potential,"

"target," "intend," "seek," "will," "would," "could," "should," "forecast," or the negative or plural of these words, or other similar expressions that are predictions or indicate future events, trends or prospects but the absence of these words

does not necessarily mean that a statement is not forward-looking. Any statements that refer to expectations, projections, indications of, and guidance or outlook on, future earnings, dividends or financial position or performance or other

characterizations of future events or circumstances are also forward-looking statements. All forward-looking statements are based on estimates and assumptions that are inherently uncertain and that could cause actual results to differ materially

from expected results. Many of these factors are beyond the Company's ability to control or predict. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any

event, change or other circumstances that could give rise to the termination of any definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against HSAC2, the combined

company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of

HSAC2, or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory

approval of the Business Combination; (5) the ability to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of the Company

as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the

combined company to commercialize its product candidates, maintain relationships with physicians and suppliers and retain its management and key employees; (8) costs related to the Business Combination; (9) changes in applicable laws or

regulations; (10) the possibility that the Company or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the Company's estimates of expenses and profitability; (12) the risks and

uncertainties set forth on the slides titled "Summary of Risk Factors" located in the appendix to this Presentation; and (13) other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Forward Looking Statements" in

HSAC2's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 31, 2022. There may be additional risks that neither HSAC2 nor the Company presently know or that HSAC2 and the Company currently believe

are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. 2

Important Notice and Disclaimer (Cont'd) 3 You are cautioned not to place undue reliance upon any forward-looking statements. Any

forward-looking statement speaks only as of the date on which it was made, based on information available as of the date of this Presentation, and such information may be inaccurate or incomplete. The Company undertakes no obligation to publicly

update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Information regarding performance by, or businesses associated with, our management team or businesses

associated with them is presented for informational purposes only. Past performance by the Company's management team and its affiliates is not a guarantee of future performance. Therefore, you should not rely on the historical record of the

performance of the Company's management team or businesses associated with them as indicative of the Company's future performance of an investment or the returns the Company will, or is likely to, generate going forward. Industry and Market

Data In this Presentation, the Company may rely on and refer to certain information and statistics obtained from third-party sources which they believe to be reliable. The Company has not independently verified the accuracy or completeness of

any such third-party information. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any such third-party information. Trademarks HSAC2 and the Company own or have rights to

various trademarks, service marks and trade names that they use in connection with the operation of their respective businesses. This Presentation may also contain trademarks, service marks, trade names and copyrights of third parties, which are

the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this Presentation is not intended to, and does not imply, a relationship with HSAC2 or the Company, or an

endorsement or sponsorship by or of HSAC2 or the Company. Solely for convenience, the trademarks, service marks, trade names and copyrights referred to in this Presentation may appear without the TM, SM, * or symbols, but such references are

not intended to indicate, in any way, that HSAC2 or the Company will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks, trade names and

copyrights. Additional Information In connection with the proposed Business Combination, HSAC2 intends to file a preliminary and definitive proxy statement/prospectus, which will be a part of a registration statement, and other relevant

documents with the SEC relating to the proposed Business Combination . This Presentation does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any

investment decision or any other decision in respect of the Business Combination. HSAC2's and the Company's shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the

amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about HSAC2, the Company and the Business

Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to shareholders of HSAC2 as of a record date to be established for voting on the proposed

Business Combination. Shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC's

website at www.sec.gov, or by directing a request to: Health Sciences Acquisitions Corporation 2; 40 10th Avenue, Floor 7, New York, NY 10014. Participants in the Solicitation HSAC2 and its directors and executive officers may be deemed

participants in the solicitation of proxies from HSAC2's shareholders with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in HSAC2 is contained in

HSAC2's Annual Report on Form 10-K, which was filed with the SEC on March 31, 2022 and is available free of charge at the SEC's web site at www.sec.gov, or by directing a request to Health Sciences Acquisitions Corporation 2; 40 10th Avenue,

Floor 7, New York, NY 10014. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed Business Combination when available. The Company and its directors and

executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of HSAC2 in connection with the proposed Business Combination. A list of the names of such directors and executive officers and

information regarding their interests in the proposed Business Combination will be included in the proxy statement/prospectus for the proposed Business Combination when available. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN

APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN ANY REPRESENTATION TO THE CONTRARY IS A

Transaction Overview 4 Transaction Summary Orchestra BioMed and Health Sciences Acquisitions Corporation 2 ("HSAC2", Nasdaq: HSAQ)

have entered into a definitive business combination agreement HSAC2 is a special purpose acquisition company sponsored by RTW Investments, LP Upon closing, HSAC2 will change its name to "Orchestra BioMed Holdings, Inc." and is expected to trade

under ticker "OBIO" Expected post transaction implied pro forma fully diluted equity value of $317 million and pro forma fully diluted enterprise value of $158 million1 Transaction expected to close Q4 2022 Cash in Trust Deal structured to

provide a minimum of $70 million in gross cash to the combined company from HSAC2's trust RTW is providing up to a $50 million commitment to backstop potential redemptions $20 million in total forward purchase agreements from Medtronic and

RTW Assuming no redemptions are made, an additional $90 million may be available from HSAC2's trust account, providing maximum gross proceeds from the business combination of $160 million Earnout for Orchestra Shareholders 8M shares subject

to milestones being achieved 50% at 20-day VWAP of $15.00/sh and 50% at 20-day VWAP of $20.00/sh, any time in 5 years following business combination closing Opt-in requires an extended lock-up of 12 months Sponsor Shares and Private Placement

Warrants Deferred Sponsor Shares Vesting 1M shares (25% of 4M sponsor shares) subject to vesting milestones being achieved 50% at 20-day VWAP of $15.00/sh and 50% at 20-day VWAP of $20.00/sh, any time in 5 years following business combination

closing Sponsor Private Placement Warrants issued at IPO Sponsor agreed to extinguish 50% or 750,000 of its pre-paid Private Placement Warrants that have an exercise price of $11.50/sh and expire 5 years following completion of a business

combination Use of Proceeds Orchestra BioMed expected to have a minimum total pro forma cash of $169 million, after expenses at announcement1 The combined company is expected to have sufficient capital into 2026 based on current plans and

estimates 1Assumes company cash balance at 3/31/2022 pro forma for Avenue Capital Loan and Security Agreement and Series D preferred stock offering. Assumes minimum gross cash case of $70 million. If no redemptions, the company could have total

pro forma cash of up to $259 million.

Terms of Transaction 5 Combination is structured to provide a minimum of $70 million in gross cash to the combined company Sources

& Uses (Minimum G Sources ross Cash Case) Amount Pro Forma Valuation (Minimum Particulars Gross Cash Case) Amount Cash Held in Trust 1 $70,000,000 Share Price $10.00 Orchestra Fully Diluted Equity 2 3 213,000,000 Pro Forma Fully

Diluted Shares Outstanding 2 3 31,750,000HSAC2 Sponsor Shares 34,500,000 P Forma Fully Diluted Equity Value $317,500,000 Total Sources $317,500,000 (-) Net Trust Cash 1 (58,000,000) (-) Existing Balance Sheet Cash (111,350,000) (+)

Debt 10,000,000 Pro Forma Fully Diluted Enterprise Value $158,150,000 Pro Forma Basic Ownership Uses Amount Orchestra Fully Diluted Equity

Orchestra BioMed Executive Summary Strategic collaboration with Medtronic Strong balance sheet with significant financial runway

and outstanding investors Medtronic Partnership-enabled business model designed to accelerate innovation to patients, drive strong partner and shareholder value, & yield exceptional future profitability Statistically significant

double-blind, randomized preliminary trial efficacy data Plan to initiate pivotal trial H2 2023 Strategic partnership with Strong 3-year multi-center preliminary trial safety and efficacy data Plan to initiate pivotal trial H1

2023 6 BackBeat CNT targets >$10B annual hypertension market Firmware upgrade to exis:ng pacemaker Virtue SAB targets $3B annual artery disease markets Protected sirolimus delivery, non-coated balloon

Enable new growth opportunities Outsource development Minimize P&L dilution 7 Orchestra BioMed's Partnership-enabled Model

Benefits All Development Strategic Partners Commercializa0on Improve patient lives Accelerate development Leverage expertise & resources Secure high-margin long-term royalties Outsource commercialization Multiply pipeline

opportunities Shared Benefits

Advancing a High-Impact Pipeline 8 *Plan to leverage existing coronary ISR data to support potential Pivotal Study; **Estimated

global annual market opportunity for 2025. Virtue SAB has received Breakthrough Device Designation for: 1The balloon dilatation of the stenotic portion (up to 26 mm length) of a stented coronary artery (in-stent restenosis (ISR)) that is 2.25

to 4.0 mm in diameter, for the purpose of improving lumen diameter; 2The balloon dilation of the de novo stenotic portion (up to 26mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for

the purpose of improving lumen diameter; 3The balloon dilatation of the stenotic portion (up to 18 mm length) of an infrapopliteal artery (P-3 segment or distal, below the knee, with reference vessel diameter (RVD) 2.25 - 4.0 mm), for the

purpose of improving lumen diameter. Definition: First-In-Human (FIH) Product Platforms Target Indications Preclinical Pivotal Estimated Market** Partner Next Milestone & Expected Timing BackBeat Cardiac Neuromodulation Therapy

(CNT ) Hypertension (HTN) (pacemaker patients) High-Risk HTN (non-pacemaker patients) CE Mark >$2 Billion Medtronic Global Pivotal Trial Initiation H2 2023 >$8 Billion Plan to Leverage Data from HTN+P CNT - HF Heart

Failure >$3 Billion Acute FIH Data 2023; Chronic Study H2 2023 Virtue Sirolimus AngioInfusion Balloon (SAB) Coronary In-Stent Restenosis (ISR) Coronary Small Vessel (SV)* Below-the-Knee (BTK)* FDA Breakthrough1 US ISR Pivotal

Trial Initiation H1 2023 FDA Breakthrough2 $3 Billion Japan SV-ISR Study H2 2023 FDA Breakthrough3 US SV and Global BTK Studies 2024 SirolimusEFR Injection/ Direct Application Osteoarthritis Ophthalmic Inflammation >$1 Billion

Each Lead Program Selection 2023 SirolimusEFR Microporous Balloon Delivery BPH & Strictures Chronic Rhinosinusitis >$1 Billion Each Lead Program Selection 2023

George Papandreou Inessa R. Wheeler Bob Laughner Stephen A. Zielinski Ziv Belsky Juan Lorenzo Bill Baumbach, Ph.D. Eileen

Bailey SVP, Quality VP, Strategy & VP, Regulatory Affairs VP, Product Dev., VP, Research, VP, Product Dev., VP, Scientific Affairs, VP, Quality, Focal Marketing Bioelectronic Therapies Bioelectronic Therapies Focal

Therapies Focal Therapies Therapies Highly Accomplished Executive Team & Board Executive Team: >250 Years of Experience, ~25 Avg Industry Years, >100 Product Approvals & >600 Authored Patents David Hochman Chairman, CEO,

Co-Founder Darren R. Sherman President, COO, Director, Co-Founder Michael Kaswan Chief Financial Officer Dennis Donohoe, M.D. Chief Medical Officer Yuval Mika, Ph.D. GM & CTO, Bioelectronic Therapies Hans-Peter Stoll, M.D.,

Ph.D. Chief Clinical Officer 9 Eric S. Fain, M.D. Board Member Eric A. Rose, M.D. Board Member Pamela Connealy Board Member Geoffrey W. Smith Board Member Jason Aryeh Board Member

10 BackBeat Cardiac Neuromodulation Therapy (CNT )

BackBeat CNT Overview 1Company estimates based on published sources, including National Inpatient Survey (NIS) and National

Health and Nutrition Examination Survey 11 (NHANES); 2Kalaras et al. Journal of the American Heart Association. ahajournals.org/doi/10.1161/JAHA.120.020492; 3Burkhoff. MODERATO II Study 2- Year Results TCT 2021;. Definitions: Ambulatory

Systolic Blood Pressure (aSBP) and Office Systolic Blood Pressure (oSBP) Opportunity Hypertension is #1 comorbidity in pacemaker population affecting over 70% of patients1 Older population at increased risk for major events & challenges

with drug compliance Innovation Bioelectronic therapy designed to substantially & persistently lower blood pressure Compatible with standard pacemaker device & leverages existing treatment paradigm Compelling clinical data from

double-blind randomized study: significant 8.1 mmHg net reduction in 24-Hr aSBP at 6 months & 17.5 mmHg reduction in oSBP at 2 years2,3 Collaboration with Medtronic Global pacemaker leader providing technology and